Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

How Sharesies is providing ‘patient’ capital for listeds
Finance

How Sharesies is providing ‘patient’ capital for listeds

The online platform is being tapped for bookbuilds and dividend reinvestment plans.

NZX rallies 0.87% as tariff uncertainty eases
Markets Market Close

NZX rallies 0.87% as tariff uncertainty eases

Skellerup bounced 4.11% as investors digested easing tariffs. 

Gregor Thompson 13 May 2025
Flick not profitable before $70m sale to Meridian
Markets

Flick not profitable before $70m sale to Meridian

After eight years of trying in electricity retailing, Z throws in the towel.

Ian Llewellyn 13 May 2025
Vista to take 25 Picturehouse Cinema sites to the cloud in 2025
Markets

Vista to take 25 Picturehouse Cinema sites to the cloud in 2025

The listed cinema software firm has its AGM on May 21.